Related Experiment Videos
[Postoperative malignant hyperthermia in a 7-day-old infant?]
K Püschel1, E Koops, J G Schulz-Baldes
1Institut für Rechtsmedizin, Universität Hamburg.
Der Anaesthesist
|February 1, 1989
Summary
Malignant hyperthermia can unexpectedly occur postoperatively in newborns, even after routine surgery. Prompt diagnosis and dantrolene treatment are crucial for this life-threatening condition.
Area of Science:
- Anesthesiology
- Pediatric Surgery
- Medical Genetics
Background:
- Malignant hyperthermia (MH) is a rare, severe pharmacogenetic disorder of skeletal muscle.
- It is triggered by volatile anesthetics and succinylcholine, leading to a hypermetabolic state.
- Neonates are susceptible, with potential for severe complications.
Observation:
- A 7-day-old male infant experienced malignant hyperthermia postoperatively.
- The triggering event was general anesthesia involving succinylcholine and halothane/nitrous oxide for a routine procedure.
- The infant presented with a typical, severe MH crisis, including hyperthermia reaching 43.7°C.
Findings:
- The patient's clinical course was characteristic of malignant hyperthermia.
- Despite medical intervention, the infant succumbed to the hypermetabolic crisis 30 hours after anesthesia.
- This case highlights the potential for unexpected MH onset in the postoperative period.
Implications:
- Medical personnel must be vigilant for malignant hyperthermia in the postoperative setting, particularly in pediatric patients.
- Early recognition and diagnosis of MH are critical for timely and effective management.
- Prompt administration of dantrolene is the primary treatment for malignant hyperthermia and can be life-saving.